Share Twitter LinkedIn Facebook Email Sara Tolaney, MD from Dana Farber Cancer Institute speaks about the SABCS 2021 Presentation – Heterogeneity in treatment outcomes for HER2+ breast cancer – clinical management strategies.
Atezolizumab Stumbles in Triple Negative Breast Cancer Study: SABCS 2024 Results with Charles Geyer Breast 4 Mins Read